This podcast episode features European perspectives on some of the most important new antiretroviral therapy insights from HIV research over the past year, including findings from real-world and long-term studies of 2-drug oral regimens, the latest on 2-drug long-acting injectable therapy, and other new and emerging innovations in HIV treatment.
In this episode, 2 European HIV experts share their thoughts on some of the most important new antiretroviral therapy insights from HIV research over the past year.
Specifically, the faculty discuss findings from real-world and long-term studies of 2-drug oral regimens, the latest on 2-drug long-acting injectable therapy, how 2-drug options fit into rapid start strategies, and other new and emerging innovations in HIV treatment, including the availability of lenacapavir for multidrug-resistant HIV treatment and resumption of islatravir clinical development.
Presenters:
Jürgen K. Rockstroh, MD
Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany
Alexandra Calmy, MD, FMH, PhD
HIV/AIDS Unit Director
Infectious Diseases Division
Geneva University Hospitals
University of Geneva
Geneva, Switzerland
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare.
Link to full program:
http://bit.ly/3Hz0jNa